PYC's science is cutting-edge. No one can doubt it's validation, when we are told PYC and Professor Ventikaraman's team at Cambridge university are in intense negotiations concerning ongoing research.
PYC were very happy with Roche/PYC stage 1 results. If Roche were not to run with PYCs technology, it would most likely be offered to their competitors.
At present it seems Roche is out in front with research into reaching targets within cells. Are they going to let the best science slip through their fingers?
As said in previous posts, Roche are first to really see the value of PYCs technology. The ball is in their court.
Mrs Peel, my other shares don't excite like PYC
Cheers ST
47m 15c options august 2011: in the money, page-13
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
0.005(2.70%) |
Mkt cap ! $886.5M | |||
| Open | High | Low | Value | Volume |
| 18.5¢ | 19.0¢ | 17.5¢ | $508.8K | 2.763M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 118941 | 18.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.0¢ | 183634 | 2 |
| Last trade - 16.10pm 14/11/2024 (20 minute delay) ? |
| PYC (ASX) Chart |
Day chart unavailable